As the conversation around Big Pharma centers on looming patent cliffs and the search for major revenue drivers, small drugmakers are just as eager to find blockbuster opportunities -- and Rapport Therapeutics may have found one.
Following a Phase 2 trial success on Tuesday, Jefferies analyst Andrew Tsai expects Rapport's lead pipeline candidate, RAP-219, to reach billions of dollars in peak sales.
RAP-219 achieved a statistically significant 3.1-point placebo-adjusted improvement on the Young Mania Rating Scale (YMRS) -- a clinician-administered tool used to measure manic symptom severity -- after three weeks of treatment. The trial enrolled 253 patients with bipolar I disorder experiencing a manic episode.
Rapport said the results support advancing to late-stage trials, which it aims to initiate in the second half of 2027.
Investors welcomed the news. Shares of Rapport Therapeutics surged 23% to $35.13 in premarket trading Tuesday, far outpacing the broader market and setting them up for their largest single-day percentage gain since September 2025. Sector peer Xenon Pharmaceuticals rose 2.1%.
This candidate remains a ways off from regulatory consideration, but analysts see a transformative opportunity. Tsai believes the latest results expand RAP-219's total addressable market while offering a positive read-through for ongoing late-stage trials in focal onset seizures.
As Rapport's market capitalization currently sits around $1.4 billion, Tsai argues the market is overlooking much of the drug's potential. He estimates the core focal epilepsy franchise alone is worth $2.2 billion, leaving the bipolar mania indication as an unpriced $1 billion-plus optionality for investors.
Goldman Sachs is similarly constructive on RAP-219 as a novel epilepsy medication, citing strong patient interest in new treatment options. While early efficacy signals are encouraging, analysts cautioned last month that "validation is needed per a larger, randomized Phase 3 study."
Even so, as Tsai pointed out, RAP-219's existing safety and efficacy data from focal epilepsy trials help build confidence in the drug. Under the right circumstances, regulators may accept a single well-controlled Phase 3 trial to support approval.
Comments